Product Description
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for MK-7480](https://pryzm-maps.s3.us-west-2.amazonaws.com/7current_maps.png)
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Fatty Liver, Alcoholic
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2071240015 | P1 |
Not yet recruiting |
Fatty Liver, Alcoholic |
2025-02-12 |